Anticoagulation with atrial fibrillation;Antikoagulation bei vorhofflimmern

Herzschrittmachertherapie und Elektrophysiologie

Volumn 17, Issue 2, 2006, Pages 89-94

  Zellerhoff, S ^a   Goette, A ^b   Kirchhof, P ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Drugs; Risk; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DABIGATRAN; FLUINDOSTATIN; HEPARIN; HIRUDIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPIRUDIN; MEVINOLIN; PHENPROCOUMON; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

AGING; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; PATIENT MONITORING; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 33745291988     PISSN: 09387412     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00399-006-0515-z     Document Type: Review

References (40)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama 285:2370-2375
2. Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Böcker D, Breithardt G, Haverkamp W, Borggrefe M (2002) Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 360:1275-1279
3. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK et al (2005) Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352:1861-1872
4. Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquie JL, Scavee C et al (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351:2373-2383
5. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, Gulletta S, Gugliotta F, Pappone A, Santinelli V et al (2003) Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 42:185-197
6. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, Bates ER, Lehmann MH, Vicedomini G, Augello G et al (2006) Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 354:934-941
7. Cox JL (2004) Cardiac surgery for arrhythmias. Pacing Clin Electrophysiol 27:266-282
8. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH (2004) Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 43:47-52
9. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N et al (2004) Prevention of atrial fibrillation after cardioversion: results of the PA-FAC trial. Eur Heart J 25:1385-1394
10. AFFIRM, Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833
11. Van Gelder I, Hagens VE, Bosker HA, Kingma H, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermanns AJM, Tijssen JGP et al (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840
12. Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim MH et al (2005) Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 165:1185-1191
13. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G (1996) Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 46:1301-1305
14. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS (1996) Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 27:1765-1769
15. Conway DS, Pearce LA, Chin BS, Hart RG Lip GY (2003) Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with non-valvular atrial fibrillation. Circulation 107:3141-3145
16. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983-988
17. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy, D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946-952
18. Hart RG, Benavente O, McBride R, Pearce LA (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131:492-501
19. Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540-546
20. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019-1026
21. Rockson SG, Albers GW (2004) Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 43:929-935
22. Taylor FC, Cohen H, Ebrahim S (2001) Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. Bmj 322:321-326
23. Hohnloser, SH, Connolly SJ (2003) Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol 14:S60-S63
24. Olsson SB (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691-1698
25. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Jama 285:2864-2870
26. Man-Son-Hing M, Laupacis A (2003) Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 163:1580-1586
27. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S (2004) Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:287S-S310S
28. Gurm HS, Bhatt DL (2005) Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors. Am Heart J 149:S43-S53
29. Albers GW (2004) Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am J Manag Care 10:S462-S469; discussion S469-S473
30. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P et al (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. Jama 293:690-698
31. Ostermayer SH, Reisman M, Kramer PH, Matthews RV, Gray WA, Block PC, Omran H, Bartorelli AL, Della Bella P, Di Mario C et al (2005) Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 46:9-14
32. Lown B, Perlroth M, Kaidbey S, Abe T, Harken DE (1963) Cardioversion of atrial firbrillation. A report on the treatment of 65 episodes in 59 patients. N Engl J Med 269:325-331
33. Bjerkelund CJ, Orning OM (1969) The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 23:208-216
34. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S et al (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 22:1852-1923
35. Weigner MJ, Thomas LR, Patel U, Schwartz JG, Burger AJ, Douglas PS, Silverman DI, Manning WJ (2001) Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med 110:694-702
36. Nabavi DG, Allroggen A, Reinecke H, Kemeny V, Droste DW, Breithardt G, Ringelstein EB (2001) Absence of circulating microemboli in patients with atrial fibrillation undergoing electric cardioversion. Cerebrovasc Dis 11:95-99
37. Nattel S, Opie LH (2006) Controversies in atrial fibrillation. Lancet 367:262-272
38. http://en.sanofi-aventis.com/press/pp-c_2647.asp, Zugriff am 18. 3. 2006
39. http://www.cardiosource.com/pops/trialSum.asp?trialID=1397, Zugriff am 18. 3. 2006
40. http://www.cardiosource.com/rapidnewssummaries/index.asp?EID=22&DoW= Tues&SumID=157, Zugriff am 18. 3. 2006